Skip to main content

Table 5 Prevalence of comorbidity in the study patients according to the baseline NLR

From: Clinical utility of blood neutrophil-lymphocyte ratio in Japanese COPD patients

n (%) NLR < 2.7 NLR ≥ 2.7 p-value
Benign prostatic hyperplasia 30 (15.3) 10 (15.2) 0.976
Tuberculosis 17 (8.7) 5 (7.6) 0.781
Arteriosclerosis obliterans 1 (0.5) 2 (3.0) 0.096
Aortic aneurysm 7 (3.6) 2 (3.0) 0.835
Arrhythmia 23 (11.7) 6 (9.1) 0.554
Heart failure 13 (6.6) 2 (3.0) 0.276
Coronary artery disease 23 (11.7) 8 (12.1) 0.933
Peptic ulcer disease 13 (6.6) 4 (6.1) 0.870
Dyslipidemia 35 (17.9) 10 (15.2) 0.614
Diabetes mellitus 30 (15.3) 8 (12.1) 0.525
Hypertension 71 (36.2) 23 (34.9) 0.840
Interstitial pneumonia 38 (26.8) 12 (35.3) 0.322
Pneumothorax 10 (5.1) 3 (4.6) 0.857
Hyperuricemia 16 (8.2) 6 (9.1) 0.814
Cerebral infarction 11 (5.6) 5 (7.6) 0.565
Asthma (Asthma COPD overlap) 38 (19.5) 16 (24.2) 0.410
Depression 15 (7.7) 9 (14.1) 0.124
Cancer 36 (18.4) 19 (28.7) 0.072
Cataract 58 (38.7) 24 (53.3) 0.081
  1. NLR Neutrophil-to-Lymphocyte ratio, COPD chronic obstructive pulmonary disease